Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Clinical Pharmacology
|
March 6, 2003
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function
Andrej Skerjanec, James Berenson, ChyiHung Hsu, et al.
Genes
|
January 12, 2018
Physiological and Comparative Genomic Analysis of Arthrobacter sp. SRS-W-1-2016 Provides Insights on Niche Adaptation for Survival in Uraniferous Soils
Ashvini Chauhan, Ashish Pathak, Rajneesh Jaswal, et al.
Cancer Investigation
|
November 22, 2002
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate
Allan Lipton, E Small, Fred Saad, et al.
Retina (Philadelphia, Pa.)
|
January 27, 2023
QUANTITATIVE ASSESSMENT OF AUTOMATED OPTICAL COHERENCE TOMOGRAPHY IMAGE ANALYSIS USING A HOME-BASED DEVICE FOR SELF-MONITORING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Jonathan D Oakley, Steven Verdooner, Daniel B Russakoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2005
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
Robert E Coleman, Pierre Major, Allan Lipton, et al.
Journal of Clinical Pharmacology
|
November 5, 2002
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
Tianling Chen, James Berenson, Robert Vescio, et al.
Cancer
|
December 24, 2003
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
Lee S Rosen, David H Gordon, William Dugan, et al.
Cancer
|
June 16, 2004
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial
Lee S Rosen, David Gordon, N Simon Tchekmedyian, et al.
The British Journal of Ophthalmology
|
May 4, 2026
Impact of AI-enhanced three-dimensional OCT scans on disease activity assessment in patients with nAMD: the RAZORBILL study
Karsten U Kortuem, Javier Zarranz-Ventura, Francesco Bandello, et al.
American Journal of Ophthalmology
|
May 27, 2018
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma
Rebecca Stacy, Kenneth Huttner, Jen Watts, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Clinical Pharmacology
|
March 6, 2003
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function
Andrej Skerjanec, James Berenson, ChyiHung Hsu, et al.
Genes
|
January 12, 2018
Physiological and Comparative Genomic Analysis of Arthrobacter sp. SRS-W-1-2016 Provides Insights on Niche Adaptation for Survival in Uraniferous Soils
Ashvini Chauhan, Ashish Pathak, Rajneesh Jaswal, et al.
Cancer Investigation
|
November 22, 2002
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate
Allan Lipton, E Small, Fred Saad, et al.
Retina (Philadelphia, Pa.)
|
January 27, 2023
QUANTITATIVE ASSESSMENT OF AUTOMATED OPTICAL COHERENCE TOMOGRAPHY IMAGE ANALYSIS USING A HOME-BASED DEVICE FOR SELF-MONITORING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Jonathan D Oakley, Steven Verdooner, Daniel B Russakoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2005
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
Robert E Coleman, Pierre Major, Allan Lipton, et al.
Journal of Clinical Pharmacology
|
November 5, 2002
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
Tianling Chen, James Berenson, Robert Vescio, et al.
Cancer
|
December 24, 2003
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
Lee S Rosen, David H Gordon, William Dugan, et al.
Cancer
|
June 16, 2004
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial
Lee S Rosen, David Gordon, N Simon Tchekmedyian, et al.
The British Journal of Ophthalmology
|
May 4, 2026
Impact of AI-enhanced three-dimensional OCT scans on disease activity assessment in patients with nAMD: the RAZORBILL study
Karsten U Kortuem, Javier Zarranz-Ventura, Francesco Bandello, et al.
American Journal of Ophthalmology
|
May 27, 2018
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma
Rebecca Stacy, Kenneth Huttner, Jen Watts, et al.
Page
of 3